ARS Pharmaceuticals Outlines Strategic Priorities, including a Focused Commercial Strategy, and Reports Second Quarter 2026 Financial Results
ARS Pharmaceuticals Announces Conference Call and Webcast on August 13 Outlining its Updated Strategic Priorities and Reporting Second Quarter 2026 Financial Results
ARS Pharmaceuticals Strengthens Leadership Team with Appointment of Industry Veteran Donn Casale as President
ARS Pharmaceuticals Announces Conference Call and Webcast for its First Quarter 2026 Financial Results
neffy® Approved in Canada as the First and Only Needle-Free Emergency Treatment of Allergic Reactions
ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Updates on neffy® Commercialization
ARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2025 Financial Results and Participation at Upcoming Conferences
ARS Pharmaceuticals to Showcase Scientific Innovation and Robust Clinical Data on neffy® at 2026 American Academy of Allergy, Asthma and Immunology Annual Scientific Meeting
EURneffy® 1 mg Recommended for Approval in the EU for Emergency Treatment of Type 1 Allergic Reactions, including Anaphylaxis in Children Weighing ?15 kg to <30 kg
California K-12 Schools Now Eligible for neffyinSchools Program, Offering Needle-Free Epinephrine at No Cost for Emergency Use
Equity Metals Announces a Significant Increase to the Mineral Resource Estimate at the Silver Queen Project, BC
Lahontan Consolidates Ownership of West Santa Fe, Eliminates Royalties, and Adds Strategic New York Canyon Project Through Acquisition of Emergent Metals
West High Yield Resources Receives Occupant Licence to Cut and Remove, Marking Another Major Regulatory Milestone at Record Ridge Magnesium Project
Metalsource Mining Extends High Grade Mineralization at Depth as Silver Hill Exploration Enters Major Expansion Phase
